Active, not recruitingPhase 3NCT02411448
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eli Lilly and Company
- Principal Investigator
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Eli Lilly and Company
- Intervention
- Ramucirumab(drug)
- Enrollment
- 545 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2026
Study locations (30)
- UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
- St. Charles Health System, Denver, Colorado, United States
- The Gastroenterology Group, P.C., Honolulu, Hawaii, United States
- Cancer Center of Kansas, Wichita, Kansas, United States
- Queens Medical Associates, Fresh Meadows, New York, United States
- Levine Cancer Institute, Charlotte, North Carolina, United States
- AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
- Cross Cancer Institute, Edmonton, Alberta, Canada
- Hôpital Arnaud de Villeneuve - CHU Montpellier, Montpellier, Hérault, France
- Chu Grenoble Alpes, La Tronche, Isère, France
- Hopital Claude Huriez - CHU de Lille, Lille, Nord, France
- Centre Hospitalier Universitaire de Poitiers, Poitiers, Vienne, France
- Hôpital Européen Georges Pompidou, Paris, France
- Robert-Bosch-Krankenhaus, Gerlingen, Baden-Wurttemberg, Germany
- Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden-Wurttemberg, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02411448 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07086456Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerSun Yat-sen University
- RECRUITINGNANCT07086300Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCKong Fanming
- RECRUITINGPHASE2NCT06620835Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibGroupe Francais De Pneumo-Cancerologie
- RECRUITINGPHASE1, PHASE2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc.
- RECRUITINGPHASE3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCDr Arvindran A/L Alaga
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →